OTLK Earnings — Outlook Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
OTLK — Outlook Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$0.73
Market Cap$102.2M
P/E—
52W Range$0.16 – $3.39
Next Earnings2026-08-13
About Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
